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Many neurodegenerative diseases are characterized
by the accumulation of insoluble protein aggregates,
including neurofibrillary tangles comprised of tau
in Alzheimer’s disease and Lewy bodies composed
of a-synuclein in Parkinson’s disease. Moreover,
different pathological proteins frequently codeposit
in disease brains. To test whether aggregated a-syn-
uclein can directly cross-seed tau fibrillization, we
administered preformed a-synuclein fibrils assem-
bled from recombinant protein to primary neurons
and transgenic mice. Remarkably, we discovered
two distinct strains of synthetic a-synuclein fibrils
that demonstrated striking differences in the effi-
ciency of cross-seeding tau aggregation, both in
neuron cultures and in vivo. Proteinase K digestion
revealed conformational differences between the
two synthetic a-synuclein strains and also between
sarkosyl-insoluble a-synuclein extracted from two
subgroups of Parkinson’s disease brains. We specu-
late that distinct strains of pathological a-synuclein
likely exist in neurodegenerative disease brains
and may underlie the tremendous heterogeneity of
synucleinopathies.INTRODUCTION
A common feature of many neurodegenerative diseases is the
accumulation of normally soluble proteins into filamentous insol-
uble aggregates. Examples include tau neurofibrillary tangles
(NFTs) in Alzheimer’s disease (AD) and frontotemporal degener-
ation (reviewed by Lee et al., 2001) and a-synuclein (a-syn) Lewy
bodies (LBs) in Parkinson’s disease (PD) and dementia with LB
(DLB) (reviewed by Goedert et al., 2013). Whereas tau is a micro-
tubule-binding protein that stabilizes and promotes microtubule
assembly in axons (Witman et al., 1976), a-syn is a phospholipid-
binding protein concentrated in presynaptic terminals where it
promotes SNARE complex formation and modulates synapticfunctions (Burre´ et al., 2010; Murphy et al., 2000). Although the
mechanisms whereby tau and a-syn aggregates induce neuro-
degeneration are not understood, they are thought to contribute
to neuronal dysfunction and death through loss of normal func-
tions and/or toxic gains of functions (reviewed by Ballatore
et al., 2007; Goedert, 2001).
Both tau and a-syn are natively unfolded soluble proteins
without well-defined secondary or tertiary structures (Weinreb
et al., 1996), but how they undergo conformational changes to
become insoluble and form aggregates is unclear. Recently,
increasing evidence supports robust aggregation of tau and
a-syn induced by exogenously supplied preformed fibrils (pffs)
in cultured cells, as well as in living animals, suggesting that
small amounts of misfolded protein can act as seeds to initiate
templated recruitment of their soluble counterparts into fibrils
(Frost et al., 2009; Guo and Lee, 2011; Iba et al., 2013; Luk
et al., 2009, 2012a, 2012b; Volpicelli-Daley et al., 2011). More-
over, cell-to-cell transmission of these amyloid protein aggre-
gatesmay underlie the stereotypical spatiotemporal progression
of both AD and PD pathologies (reviewed by Jucker and Walker,
2011).
Another recurrent theme of neurodegenerative diseases is the
frequent co-occurrence of different disease protein aggregates
in the same patient. For example, >50% of AD cases show
LBs, whereas co-morbid AD pathologies, including Ab plaques
and NFTs, are commonly found in PD and DLB brains (reviewed
by Galpern and Lang, 2006). One potential explanation is global
dysregulation of protein homeostasis in disease brains, whereby
misfolding of one major protein overwhelms the proteostatic
machinery and compromises folding of other aggregation-prone
proteins (reviewed by Kikis et al., 2010). Alternatively, fila-
mentous aggregates composed of one protein may directly
cross-seed other amyloidogenic proteins owing to potentially
shared structural features of amyloid fibrils (Kayed et al., 2007;
O’Nuallain and Wetzel, 2002). Indeed, we showed earlier that
recombinant a-syn and tau proteins synergistically promote
the fibrillization of each other in vitro (Giasson et al., 2003),
whereas more recently, a-syn pffs were shown to induce tau ag-
gregation in cultured non-neuronal cells (Waxman and Giasson,
2011). To confirm this cross-seeding phenomenon in physiolog-
ically more relevant systems, we utilized recently developed syn-
ucleinopathy models in primary neurons and transgenic (Tg)Cell 154, 103–117, July 3, 2013 ª2013 Elsevier Inc. 103
mice, in which exogenously added a-syn pffs promote aggrega-
tion of endogenous a-syn (Luk et al., 2012b; Volpicelli-Daley
et al., 2011). By using these models, we discovered two distinct
‘‘strains’’ of synthetic a-syn pffs with differential ability to cross-
seed tau aggregation in cultured neurons and in vivo. In this
work, we define strains as conformational variants of a-syn fibrils
with differing cross-seeding properties in these cellular and
organismal contexts.
RESULTS
Generation of Different Strains of a-Syn pffs with
Differential Cross-Seeding of Tau
To investigate whether a-syn pffs cross-seed tau in primary neu-
rons, we incubated hippocampal neurons from mouse embryos
overexpressing human mutant P301S tau (PS19) with a-syn pffs
assembled de novo fromC-terminal-truncated 1–120monomers
with aMyc tag (1–120-Myc). At 18 days post-transduction, highly
abundant LB and Lewy-neurite (LN) like a-syn inclusions that are
resistant to Triton X-100 extraction were observed throughout
the cultured neurons (Figure 1A, top panel). However, Triton-
insoluble hyperphosphorylated tau aggregates were infrequent
and rarely colocalized with a-syn pathology. The lack of direct
evidence for physical interactions between a-syn and tau aggre-
gates suggests that the formation of the latter is likely an indirect
consequence of a-syn accumulation rather than a direct result of
cross-seeding by a-syn. In neurons derived from non-Tg mice,
no appreciable tau aggregates were induced (Figure 1A, bottom
panel).
Remarkably, a very different pattern of Triton-insoluble a-syn
and tau inclusions was observed in neurons treated with a prep-
aration of 1–120-Myc pffs generated through repetitive seeded
fibrillization in vitro, whereby 5% or 10% of pffs from each pas-
sage were included as seeds in the fibrillization reaction of the
subsequent passage (Figure 1B). Although a-syn pathology
was somewhat less abundant at 18 days post-transduction
compared to transduction with de novo 1–120-Myc pffs, wide-
spread fibrillar tau aggregates that extensively colocalized with
neuritic a-syn inclusions were observed in both PS19 and
non-Tg neurons (Figure 1C). Surprisingly, the extent of endoge-
nous mouse tau pathology induced in non-Tg neurons by these
a-syn pffs dramatically exceeded that induced by synthetic tau
pffs (Guo and Lee, 2013). To distinguish these two distinct types
of a-syn pffs that are reminiscent of prion ‘‘strains,’’ we designate
pffs that have limited cross-seeding ability of tau, which were
used in all our previous a-syn transmission studies, as strain A,
and the newly discovered pffs with efficient cross-seeding of
tau as strain B (Luk et al., 2009, 2012b; Volpicelli-Daley et al.,
2011) (Table S2 available online). Generation of strain B through
repeated self-seeding in vitro was reproduced using several
different batches of 1–120-Myc monomer, as confirmed by
phenotypic transition from a relative paucity of insoluble tau in
early passages to appearance of robust tau pathology in later
passages (Figure S1A).
Although strain B a-syn pffs efficiently induce endogenous tau
aggregation in non-Tg neurons, this phenomenon failed to occur
in a-syn knockout neurons (Figure 1D), suggesting that endoge-
nous mouse a-syn mediates fibrillization of mouse tau in non-Tg104 Cell 154, 103–117, July 3, 2013 ª2013 Elsevier Inc.neurons. It is conceivable that the internalized a-syn pffs them-
selves provide an insufficient quantity of nucleating structures
to directly trigger tau fibrillization, presumably due to a less effi-
cient cross-seeding of tau than homotypic seeding of a-syn,
whereas endogenous a-syn aggregates templated by internal-
ized pffs create additional seeding structures sufficient to initiate
the conversion of soluble tau into aggregates.
To test whether wild-type (WT) full-length (FL) a-syn also forms
strain A and B a-syn fibrils, non-Tg neurons were incubated for
18 days with FL a-syn pffs generated de novo (passage 1 or
P1) or through repetitive self-seeding in vitro (P2 onward) (Fig-
ure 1B). P1 pffs always behaved as strain A, resulting in profuse
a-syn inclusions with minimal tau aggregation (Figure 1E). FL
a-syn pffs of subsequent passages led to diminishing a-syn pa-
thology with small amounts of neuritic tau pathology first
emerging in neurons transduced with P4 or P5 pffs, followed
by full conversion to strain B that induced abundant tau pathol-
ogy by P6-7 (Figure 1E). Such strain A to strain B conversion
through repeated self-seeding in vitro was accomplished with
four different batches of FL a-syn monomer, although this pro-
cess did not always give rise to prototypical strain B pffs as
defined above. An intermediate phenotype with relatively abun-
dant tau pathology accompanied by far more abundant a-syn
pathology was sometimes observed (Figure S1B); this is likely
due to incomplete conversion of strain A to strain B resulting in
a mixture of the two strains. Notably, continual self-seeding
in vitro after full or partial conversion to strain B led to ‘‘strain
drift’’ within a few passages, resulting in what we refer to as
‘‘post-B strains,’’ which induce a variable amount of tau pathol-
ogy and morphologically diverse a-syn inclusions (Figure S1C;
Table S2).
Characterization of Neurons Transduced with Different
Strains of a-Syn pffs
Immunoelectron microscopy (immuno-EM) in a previous study
showed abundant phospho-a-syn-positive filaments throughout
perikarya and processes of neurons transduced with a-syn pffs
now designated as strain A (Volpicelli-Daley et al., 2011). Simi-
larly, immuno-EM also detected cytoplasmic a-syn filaments in
strain B pff-transduced neurons but mostly confined to neurites
(Figures 2A and 2B). Meanwhile, filamentous aggregates immu-
noreactive for phospho-tau were observed in neurons treated
with strain B pffs, confirming fibrillization of tau induced by het-
erotypic seeds (Figures 2C and 2D). Moreover, double-labeling
immuno-EMof strain B-transduced neurons showed close phys-
ical associations of tau with a-syn in filamentous structures in
neuronal processes (Figures 2E and 2F), strongly supporting
direct physical templating as the primary mechanism for strain
B a-syn pff-induced tau aggregation. The lack of tau immunore-
activity around occasional perikaryal a-syn-positive filaments in-
dicates specificity of our double-labeling technique (Figure 2G).
Immunocytochemistry on neurons incubated for different
durations with a-syn pffs generated from either FL or 1–120-
Myc a-syn more clearly revealed differences between the two
strains (Figures 3andS2).Non-Tgneurons transducedwith strain
Apffswere repletewith a-syn pathology in the absenceof any tau
pathology at 10 days post-transduction, but those transduced
with strain B pffs showed only sparse a-syn aggregates, whereas
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Figure 1. Generation of Different Strains of a-Syn pffs with Differential Cross-Seeding of Tau in Neurons
(A) Insoluble phospho-a-syn (81A) and phospho-tau (AT8) induced by de novo 1–120-Myc pffs (strain A) in primary hippocampal neurons dissociated from PS19
or non-Tg mouse embryos.
(B) Procedures of repetitive seeded fibrillization in vitro resulting in evolution of strain A pffs into B and post-B strains.
(C) a-syn and tau pathologies caused by seeded 1–120-Myc pffs (strain B) in PS19 and non-Tg neurons.
(D) Staining of insoluble phospho-tau (AT8, green) in a-syn knockout (a-syn KO) or non-Tg neurons transducedwith strain B 1–120-Myc pffs. DAPI (blue) revealed
cell nuclei.
(E) Phenotypic changes in a-syn and tau pathologies induced by FL a-syn pffs of different self-seeding passages.
For (A), (C), (D), and (E), neurons were fixed 18 days post-transduction, and soluble proteins were removed during fixation. Scale bar: 50 mm. See also Figure S1
and Table S2.
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Figure 2. Ultrastructural Analysis of Strain B
a-Syn pff-Induced Cytoplasmic Filaments
by Immuno-EM
(A and B) 81A-immunoreactive a-syn filaments
observed in strain B a-syn pff-transduced neurons
labeled by nanogold.
(C and D) AT8-positive tau filaments in these neu-
rons detected by nanogold.
(E–G) Double-labeling using 81A and 17025 (a pAb
against tau) as primary antibodies followed by
secondary antibodies conjugated to 10 nm
colloidal gold (for a-syn) or 6 nm colloidal gold (for
tau). (E) and (F) show filaments decorated by both
a-syn (arrowheads) and tau (arrows) antibodies
found in neurites, whereas (G) shows filaments
almost exclusively composed of a-syn found in a
cell body.
Scale bar: 500 nm for (A)–(D), 100 nm for (E)–(G).small amounts of neuritic tau accumulations already emerged
(Figures 3A andS2A). By 14 days and 18 days post-transduction,
the burden of a-syn aggregates increased in strain B-transduced
neurons, accompanied by a dramatic increase in tau aggregates,
nearly all of which colocalized with a-syn pathology (Figures
3A–3D and S2A). In contrast, strain A-induced a-syn pathology
appeared to plateau at 14 days post-transduction, but no neuritic
tau pathology ever occurred. Immunoblotting of lysates from
neurons that were sequentially extracted with 1% Triton X-100
lysis buffer followedby2%SDS lysis buffer confirmed thedistinct106 Cell 154, 103–117, July 3, 2013 ª2013 Elsevier Inc.seeding properties of the two strains of
a-syn pffs. Triton-insoluble tau was only
detected in strain B pff-transduced neu-
rons, being most prominent after 18 days
of incubation, even though Triton-insol-
uble a-syn was much more abundant in
neurons treated with strain A pffs (Figures
3E, 3F, and S2B).
Consistent with our previous study
(Volpicelli-Daley et al., 2011), strain A pffs
were highly toxic to neurons as evidenced
by significantly increased lactate dehy-
drogenase (LDH) release and reduced
metabolic activity after 14 days of incu-
bation (Figures 3G, S2C, and S2D). By
contrast, strain B pffs had no negative
impact on cell survival even after
18 days of incubation. Immunostaining
of microtubule-associated protein 2
(MAP2) and neurofilament light chain
(NFL) in 18 days post-transduction neu-
rons showed bundled but intact neuronal
processes in strain B-treated neurons,
whereas a dramatic reduction in the
density of both MAP2 and NFL and
frequent beading of dendritic MAP2 were
observed in strain A-treated neurons
(Figure S2E). The prominent reduction of
soluble tau in 18-day strain A-transducedneuron lysates was most likely a result of extensive cell death
as well (Figures 3E, 3F, and S2B).
Biophysical and Biochemical Analyses of a-Syn pff
Strains
To determine whether the distinct seeding properties of the
two a-syn pff strains reflect structural differences, a series of
biophysical and biochemical analyses were performed. First,
negative-staining transmission EM (TEM) showed no convincing
difference in the morphology of filaments (Figure S3A). Second,
ThT fluorescence signals of similar amounts of strain A and B
fibrils demonstrated wide variability without clear separation
(Figure S3B). Third, Fourier transform infrared spectroscopy
(FTIR) and circular dichroism (CD) only showedminor differences
between these two strains (Figures S3C and S3D), suggesting
that structural differences between them are subtle.
To test whether a-syn pff strains can be distinguished bio-
chemically using proteinase K (PK) digestion as demonstrated
for human prion strains (Aguzzi et al., 2007; Parchi et al., 1996),
different passages of FL a-syn pffs generated through self-
seeding in vitro were incubated with PK at 37C. The digestion
products predominantly consist of five bands between 10 and
15 kDa, with the fifth band being least abundant for P1 pffs (Fig-
ure 4A). Notably, the fifth band consistently became highly prom-
inent around P5–P7, correlating with the transition of strain A to
strain B. The relative intensity of the fifth band compared to the
first band typically shows a decline from P1 to P2, followed by
an upward trend at later passages (Figure 4B), suggesting ste-
reotypical conformational changes generated by repetitive
seeded fibrillization.
To directly examine whether the two strains of pffs show
distinct PK digestion patterns, neuronal phenotype-confirmed
strain A and B pffs were incubated with different concentrations
of PK (Figure 4C). No significant difference in overall PK resis-
tance was observed, such that no loss in the total amount of
a-syn proteins was seen after each strain was treated with PK
(Figure S3E). The first band of the PK digestion products pre-
sumably represents residual uncleaved FL a-syn pffs as it comi-
grates with FL a-syn on denaturing gels. Detailed analysis of all
five bands revealed a significantly higher ratio of cleaved species
(sum of second to fifth bands) to uncleaved a-syn (first band) for
strain B pffs at all PK concentrations (Figure 4D). This difference
was predominantly driven by increased relative abundance of
the third and fifth bands in the strain B digestion products, with
the fifth band most dramatically differentiating the two strains
at 2.5 mg/ml PK (Figures 4E, 4F, S3F, and S3G).
N-terminal sequencing indicated that both the second and
fourth bands primarily contain a-syn peptides starting around
residues 19–21, whereas the third and fifth bands both start at
residue 31 (Figure 4A). Taking into account epitope mapping
with a panel of antibodies specific to domains spanning the
entire a-syn molecule (Figure 4G), we deduced the identities of
the major PK digestion products (Figure 4H). Both the third and
fifth bands, which are more prominent in PK-digested strain
B pffs, consist of peptides N-terminally cleaved after residue
30, whereas the fifth band has an additional C-terminal cleavage
site around residue 125 (Figure 4H). Increased N- and C-terminal
truncation of strain B pffs by PK suggests that the two termini
may be more exposed for PK access in strain B than in strain
A pffs. Moreover, the two strains of pffs made from 1–120-
Myc, which lacks the C-terminal cleavage site for PK, were
clearly distinguished by an elevated amount of PK digestion
product starting at residue 31 for strain B (Figure S3H), further
supporting increased PK cleavage at the N terminus as a
biochemical signature for strain B pffs.
To further confirm that the two strains of a-syn pffs are confor-
mational variants, we generated a monoclonal antibody (mAb),
9029-03, which displays 3-fold selectivity for strain B pffsover strain A pffs as quantified by enzyme-linked immunosor-
bent assay (ELISA) (Figure 4I). This strain B-selective antibody
demonstrated an inverted U-shape curve of immunoreactivity
for different passages of a-syn pffs within each self-seeded
propagation series, consistent with the emergence of strain B
conformers after repetitive self-seeding and later conversion to
post-B strains (Figure 4J).
The Roles of N and C Termini in Strain Conformations
Because possible conformational changes of a-syn pffs at the
N and C termini correlate with phenotypic conversion from strain
A to B, we tested self-seeded pffs assembled from N- or C-ter-
minal-truncated a-syn molecules to determine whether the two
termini play causal roles in strain evolution (Figure 5A; Table
S3). Interestingly, pffs made from N-terminal-truncated a-syn
58–140 and 32–140 almost always remained incapable of
cross-seeding tau up to P10 of self-seeding despite efficient
induction of a-syn pathology (Figure 5B). The N terminus of
a-syn thus appears necessary for generating in the exogenous
a-syn pffs a cross-seeding-competent conformation that can
be conferred through templating onto endogenous a-syn, which
is required for recruiting tau (Figures 1D and 5A). Besides the
lack of tau cross-seeding, both 58–140 and 32–140 pffs
remained phenotypically stable in terms of a-syn pathology
induced by different passages of pffs in neurons. Whereas
32–140 pffs constantly behaved as strong strain A pffs, 58–140
pffs invariably led to morphologically distinct a-syn aggregates,
consisting of unusually long fibrillar accumulations in neurites
with almost no cell-body inclusions (Figure 5B). Interestingly,
when templated by 58–140 pffs in vitro, FL a-syn pffs are also
capable of acquiring similar seeding properties in neurons (Fig-
ure S4A), thus pointing to a unique conformation adopted by
58–140 pffs that can be acquired by FL a-syn.
The similar behavior of 1–120-Myc and FL a-syn in strain evo-
lution suggests that the extreme C terminus may play a minimal
role in pff conformation. Surprisingly, 1–120 without a myc tag at
the C terminus stochastically gave rise to different strains of de
novo pffs with no predictable pattern of strain conversion
through repetitive self-seeding (Figure S4B). Therefore, unlike
the N terminus of a-syn, which appears to contribute to confor-
mational diversity of fibrils, the C terminus seems to impede
structural diversity. The more predictable behavior of 1–120-
Myc may be due to enriched negative charges in the Myc tag,
which may partially mimic the natural C terminus of FL a-syn.
To test whether the N and C termini are an integral part of
strain-specific conformations, or merely facilitating the acquisi-
tion of distinct conformations by middle regions of a-syn, N- or
C-terminal-truncated a-syn proteins were fibrillized in the pres-
ence of 10%strain A or strain B pffs to test their ability to conform
to these respective strains when seeded (Figure 5A; Table S3).
For strain A-seeded fibrillization, an additional round of self-
seeding was conducted to dilute out the original strain A seeds.
1–120 a-syn faithfully acquired strain A phenotype when seeded
by strain A pffs (Figures 5C and S4C), suggesting that the
extreme C terminus is not an essential part of strain A conforma-
tion. In contrast, strain A-seeded 58–140 pffs still predominantly
induced elongated a-syn accumulations with infrequent cell-
body inclusions (Figures 5C and S4C). Therefore, the absenceCell 154, 103–117, July 3, 2013 ª2013 Elsevier Inc. 107
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of residues 1–57 impairs the acquisition of strain A conformation.
As expected from the spontaneous generation of strain A pffs,
32–140 pffs seeded by strain A always displayed typical strain
A phenotypes (data not shown), confirming that residues 1–31
are not an integral part of strain A core structure. This in turn
points to residues 32–57 as an important region of a-syn needed
to adopt the strain A configuration.
When seeded by strain B pffs, FL a-syn, 32–140, and 1–120 all
reliably acquired the ability to induce tau aggregation far beyond
what could be attributed to the 10% strain B seeds present in the
fibrillization mixture (Figures 5D, 5E, and S4D). The extensive
colocalization between endogenous a-syn and tau pathology
(Figures 5D and 5F) further supports the induction of specific
endogenous a-syn conformers that are capable of cross-seed-
ing tau. Therefore, although the initial 31 residues at the extreme
N terminus and the last 20 residues at the C terminus may facil-
itate the spontaneous generation of strain B by FL a-syn through
repetitive self-seeding, they do not constitute the core structure
of the strain B conformation. However, we did notice significantly
less-abundant aggregation of both a-syn and tau induced by
strain B-seeded 32–140 and 1–120 than by equivalently seeded
FL a-syn pffs (Figure 5E). This suggests that the lack of the
extreme N or C terminus of a-syn may result in reduced effi-
ciency in strain B-templated fibrillization. On the other hand,
strain B-seeded 58–140 pffs still behaved exactly the same as
spontaneously generated 58–140 pffs, with the sparsely distrib-
uted tau inclusions entirely accounted for by the 10% residual
strain B seeds (Figures 5D, 5E, and 5F), thereby indicating a
complete failure to adopt the strain B conformation. The striking
difference between 32–140 and 58–140 when seeded by strain B
further implicates the critical role of residues 32–57 in the gener-
ation of the strain B conformation as well.
Strain-Specific Cross-Seeding of Tau Pathology In Vivo
To test whether the two strains of a-syn pffs can differentially
induce tau pathology in vivo, we performed unilateral inoculation
of strain A or B a-syn pffs into the hippocampus of 2- to 3-month-
old PS19 mice, which overexpress human P301S mutant tau,
prior to the onset of extensive transgene-induced tau pathology
at 12 months of age (Iba et al., 2013). The induction and
spreading of tau and a-syn inclusionswere examinedwith immu-
nohistochemistry at different time points after a-syn pff inocula-
tion. At 3months post-injection, only rare cells showed abnormal
accumulation of hyperphosphorylated tau recognized by mAbFigure 3. Inverse Seeding Capacity for a-Syn and Tau Pathologies Acc
(A) Insoluble phospho-a-syn (81A) and phospho-tau (AT8) in non-Tg neurons at d
proteins were removed during fixation.
(B and C) Quantification of % area occupied by 81A- and AT8-labeled patholog
standard error of the mean [SEM]. *p < 0.05; **p < 0.01; ***p < 0.0005).
(D) Calculation of%of a-syn pathology with colocalizing tau pathology (area occu
(results shown as mean ± SEM. ***p < 0.0005; ****p < 0.0001).
(E) PS19 neurons treated with PBS or transduced with strain A or strain B FL a-sy
by 2% SDS lysis buffer (S) at different time points. Neuron lysates from T and
(phospho-tau), T49 (mouse tau), 81A (phospho-a-syn), and GAPDH antibody (loa
(F) Non-Tg neurons at 18 days post-transduction of strain A or strain B FL a-syn pf
and GAPDH antibodies.
(G) LDH assay on differently treated non-Tg neurons at 14 days and 18 days pos
Scale bar: 50 mm. See also Figure S2.AT8 near the injection site of strain A-inoculated mice, whereas
numerous neurons bearing AT8-positive tau inclusions were
observed in strain B-injected mice around the same area
(Figures 6A and 6B). Moreover, strain B-injected mice not only
displayed significantly more tau inclusions in all parts of the
hippocampus, including regions that aremore rostral and caudal
to the injection site (Figures 6A and 6B), but also consistently
showed phospho-tau aggregates in the contralateral hippocam-
pus and even locus coeruleus, a brainstem structure distant from
the injection site (Figure S5A), indicating transmission of tau
pathology cross-seeded by a-syn pffs. The differential induction
of tau aggregates by the two strains of pffs was confirmed with
MC1, a mAb specific for a pathological conformation of tau
(Jicha et al., 1997) (Figure 6C). Further characterization revealed
that tau aggregates cross-seeded by a-syn pffs were also recog-
nized by TG3, a conformational-specific phospho-tau mAb, and
Ac-K280, a polyclonal antibody (pAb) specific for acetylated tau
(Figure 6D), thus distinguishing them from spontaneously devel-
oped tau pathology in aged PS19 mice (Iba et al., 2013).
At 6 months post-injection, strain B pff-inoculated mice
continued to show significant tau pathology, although there
was only aminor increase in the rostral and caudal hippocampus
and even a slight reduction of pathology around the injection site
as compared to 3 month post-injection mice. In contrast, strain
A-injected mice demonstrated an obvious increase in phos-
pho-tau aggregates at 6 and 9 months post-injection, but the
extent of tau pathology in mice receiving strain A was far less
than that induced by strain B even at 9 months post-injection
(Figures 6A and 6B). These results clearly illustrate the greatly
enhanced tau cross-seeding capacity of strain B pffs compared
to strain A pffs in living animals, exactly as observed in cultured
neurons.
Curiously, tau pathology in a-syn pff-injected PS19 mice
occurred without substantial a-syn pathology, as only a small
number of cells bearing distinct a-syn inclusions were found in
the caudal hippocampus, regardless of strains of pffs injected
(Figures S5B and S5C). The relatively low efficiency of a-syn
pathology induction by human a-syn pffs (both strains A
and B), contrasting with our earlier study of mouse a-syn pff
inoculation into non-Tg mice (Luk et al., 2012a), could be due
to a partial species barrier that is not obvious in the less stringent
cell culture system. The overexpression of human mutant tau in
PS19mice appears to overcome the reliance on a-syn pathology
in templating tau aggregation when tau is not overexpressedompanied by Differential Cellular Toxicity
ifferent days post-transduction with strain A or strain B FL a-syn pffs. Soluble
ies, respectively, for experiments described in (A) (results shown as mean ±
pied by 81A/area occupied by AT83 100%) for strain B pff-transduced neurons
n pffs were sequentially extracted with 1% Triton X-100 lysis buffer (T) followed
S fractions were immunoblotted with 17025 (total tau), T14 (human tau), AT8
ding control).
fs were sequentially extracted and immunoblotted with AT8, T49, mouse a-syn,
t-transduction (results shown as mean ± SEM. *p < 0.05; ***p < 0.005).
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Figure 4. Conformational Differences between the Strains Revealed by PK Digestion and a Strain-Selective Antibody
(A) Different passages (P1–P7) of self-seeded FL a-syn pffs were digested with PK, resolved on 12% Bis-Tris gel, and stained with Coomassie blue. Results from
one representative series are shown. N-terminal sequencing results for the 2nd to 5th bands are presented in parentheses.
(B) Quantification of the relative intensity of the 5th band to the 1st band for experiments described in (A) for three series of self-seeded FL a-syn pffs.
(C) Pairs of strain A and B FL a-syn pffs made from the same batches of monomer were incubated with different concentrations of PK (1–2.5 mg/ml). Digestion
products from two pairs of pffs were shown. Untreated pffs were loaded on the same gels (0 mg/ml).
(legend continued on next page)
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(Figure 1D), which can account for failed induction of tau pathol-
ogy in non-Tg mice receiving hippocampal injection of either
strain of a-syn pffs up to 6 months post-injection (data not
shown).
Conformational Variations of Pathological a-Syn
in Human Brains
To assess pathological a-syn strains in human synucleinopathy
brains, we performed biochemical analysis on five cases of PD
with dementia (PDD), three of which had a secondary neuro-
pathological diagnosis of AD due to abundant NFTs and senile
plaques (Figure 7A). For all five cases, immunoblots on sarko-
syl-insoluble fraction from the cingulate gyrus showed salient
a-syn bands (Figure 7B). Although all five cases showed varying
amounts of sarkosyl-insoluble tau, it was much more abundant
in cases 3 and 4, which had higher NFT scores (Figures 7A
and 7C). Interestingly, upon PK digestion of sarkosyl-insoluble
fraction, two distinct banding patterns of a-syn were observed.
The two relatively ‘‘pure’’ PDD cases (cases 1 and 2) showed
only one prominent band running at 15 kDa, whereas the three
PDD cases with a secondary diagnosis of AD (cases 3–5)
demonstrated two prominent PK-resistant bands at 16 and
14 kDa. These results suggest that at least two conformational
variants of pathological a-syn exist in PDDbrains, but the sample
size at this stage is too small to correlate strain conformations
with pathological manifestation.
DISCUSSION
Our study demonstrates that distinct synthetic a-syn strains with
different cross-seeding tau properties can be generated in vitro.
Experiments on 32–140 and 1–120 a-syn revealed that both
N and C termini facilitate the stereotypical conversion of strain
A into strain B with continual seeding, although they themselves
are not part of the core structure for either strain. Previous struc-
tural studies suggest that the fibrillization core of a-syn spans
residues 30 to 100–110 (Comellas et al., 2011; Miake et al.,
2002; Vilar et al., 2008), extending beyond the NAC domain
(residues 61–95) that is both necessary and sufficient for a-syn
fibrillization (Giasson et al., 2001). Although 58–140with an intact
NAC domain is fully capable of seeding endogenous a-syn fibril-
lization, a unique pathological conformer distinct from strain A or
B was generated, supporting the structural role of residues on
the N-terminal side of the NAC domain in regulating a-syn fibril
conformations. Moreover, compared with 32–140, 58–140 is
deficient in acquiring either strain A or B conformation when
seeded (Table S3), suggesting that residues 32–57 constitute a(D) Quantification of the ratio of cleaved species (sum of the 2nd to 5th bands) to
shown as mean ± SEM. **p < 0.01).
(E) Quantification of the ratio of the 3rd band to the 1st band for the same samp
(F) Quantification of the ratio of the 5th band to the 1st band for the same sampl
(G) PK-digested FL a-syn pffs were immunoblotted with antibodies recognizing
(H) Deduced identities of major products from PK digestion.
(I) Different amounts of strain A or B FL a-syn pffs (0.05 to 2 mg) coated on an ELI
a-syn, and 9029-03, our newly generated strain B-selective mAb.
(J) Different passages of FL a-syn pffs immobilized on an ELISA plate were prob
For (I) and (J), absorbance for 9029-03 was expressed as % of absorbance for Hcritical part of the fibrillization core for both strains and the exact
folding of this region within fibrillar a-syn strongly influences its
seeding properties in neurons, consistent with a high-resolution
solid-state nuclear magnetic resonance (NMR) study showing
that the b strand consisting of residues 38–49 displays more
dynamic structure than other b strands in the fibril core (Comellas
et al., 2011).
The concept of ‘‘strains’’ originated from the prion field,
whereby prion variants are associated with characteristic histo-
pathological lesion profiles and different clinical manifestations
that are believed to be encoded by conformational differences
in the infectious prion particles (reviewed by Aguzzi et al.,
2007). The different synthetic a-syn conformers we describe
here closely parallel prion strains in that they exhibit structural
variations, differences in seeding properties, and heritability of
phenotypic traits via direct seeding in vitro. Our demonstration
that a spectrum of a-syn strains can arise from the simplest re-
actions in a cell-free system without any cofactors suggests
that in real human brains with a highly complex cellular and
biochemical environment, the likelihood of forming diverse
strains may be far greater. Interestingly, LBs found in midbrain
structures such as the substantia nigra are morphologically
different from those found in the cortical regions (Spillantini
et al., 1998), possibly representing distinct strains of a-syn
aggregates formed under specific cellular milieus. Moreover, in
PDD or DLB cases with concomitant AD pathologies, NFTs are
more frequently detected in limbic and neocortical areas than
in midbrain (Gearing et al., 1999; Go´mez-Tortosa et al., 2000).
This region-specific distribution of co-occurring NFTs could be
due to selective vulnerability of different brain areas to tau aggre-
gation, but it could also result from differential cross-seeding
capacity of a-syn aggregates arising in these different regions.
In fact, close physical association of tau and a-syn deposits
are frequently observed in synucleinopathies (Duda et al.,
2002; Ishizawa et al., 2003; Kotzbauer et al., 2004), supporting
direct cross-seeding between the two types of pathologies.
Besides differing cellular andbiochemical factors, other events
can also facilitate the generation of different a-syn strains in vivo.
First, C-terminally truncated a-syn has been detected in synu-
cleinopathy brains (Baba et al., 1998; Li et al., 2005). This cleav-
age event can accelerate fibrillization of a-syn (Murray et al.,
2003) and also promote stochastic formation of diverse aggre-
gated strains as shown here. Second, recent studies have impli-
cated interneuronal transmission of a-syn aggregates as the
underlying mechanism for stereotypical progression of a-syn
pathology in PD and DLB. Because every transmission event
fromoneneuron to theother canbe viewedasabona fide seededuncleaved molecules (the 1st band) for experiments described in (C) (results
les as in (D) (results shown as mean ± SEM. *p < 0.05; **p < 0.01).
es as in (D) (results shown as mean ± SEM. **p < 0.01; ***p < 0.001).
different epitopes of a-syn, indicated in parentheses.
SA plate were incubated with HuA1, a pAb raised against recombinant human
ed with HuA1 and 9029-03. Results from three series are shown.
uA1. See also Figure S3.
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fibrillization ofa-syn in the recipient neuronandour study showed
that continual seeding in vitro can lead to evolution of a-syn
strains, it is possible that transmission of a-syn pathology along
multiple neuronal connections could also give rise to divergent
pathological strains. This hypothesis could potentially account
for morphologically different LBs in substantial nigra and
neocortex, which are affected at different stages in the progres-
sion of PD and DLB (Braak et al., 2003; Kosaka et al., 1988).
Different strains of a-syn aggregates could also underlie the
tremendous heterogeneity of synucleinopathies among different
individuals (reviewed by Halliday et al., 2011). Whereas LBs and
LNs are confined to neuronal perikarya and neurites for the ma-
jority of synucleinopathies, a-syn inclusions are largely confined
to oligodendrocytes in multiple-system atrophy (Tu et al., 1998).
PDD and DLB, which belong to a continuum of LB diseases, are
clinically stratified according to the interval between the onset of
motor symptoms and cognitive deficits that can vary by decades
(Tsuboi and Dickson, 2005). Although comorbid AD pathologies
are more common in DLB than in PDD, a bimodal distribution of
neocortical NFTs has been found in DLB cases (Gearing et al.,
1999). Furthermore, the presence of two subgroups of PDD
patients has been described: one group has younger onset,
long motor-dementia interval and relatively long disease dura-
tion, and the other group has older onset, short motor-dementia
interval andmoremalignant disease course (Compta et al., 2011;
Halliday et al., 2008). The former group usually presents with only
LB pathologies, but the latter most often shows concomitant AD
pathologies. Indeed, we detected conformational variants in
sarkosyl-insoluble a-syn extracted from two subgroups of PDD
patients with differential extent of concomitant AD pathologies,
thus providing preliminary evidence for the existence of patho-
logical a-syn strains in human synucleinopathy brains.
Prior to our study, the ability for a single molecule of the same
primary sequence to adopt multiple fibril structures has been
shown for a variety of amyloidogenic proteins other than prion
protein, including Ab (Kodali et al., 2010; Petkova et al., 2005),
tau (Furukawa et al., 2011), and huntingtin with polyglutamine
expansion (Nekooki-Machida et al., 2009), although the patho-
logical relevance of amyloid fibril polymorphism other than
cellular toxicity has never been investigated in cells or animals.
The recently developed neuronal and animal models of pathol-
ogy transmission allowed us to demonstrate distinct patholog-
ical seeding properties of specific a-syn fibril types generated
in vitro. We speculate that perhaps besides interneuronal trans-
mission of aggregated proteins, the existence of conformation-
ally diverse protein strains underlying disease heterogeneity
may be another common feature of neurodegenerative diseases;
this feature was thought to be unique to prion diseases.Figure 5. The Roles of N and C Termini in Strain Conformations
(A) Schematic diagram for testing the roles of N and C termini in generating or a
(B) Pathology induced by de novo or self-seeded (P1–P10) 58–140 or 32–140 pf
(C) Insoluble a-syn aggregates resulted from 1–120 or 58–140 pffs that were init
(D) Insoluble a-syn and tau aggregates induced by FL a-syn, 58–140, 32–140, or
(E) Quantification of % area occupied by AT8-labeled tau pathology in (D) (indepe
for 58–140, n = 8 for 32–140, n = 4 for 1–120; results shown as scatterplot with m
(F) Calculation of % of a-syn pathology with colocalizing tau pathology in (D) (res
For (B), (C), and (D), soluble proteins were removed during fixation. Scale bar: 50EXPERIMENTAL PROCEDURES
Recombinant a-Syn Purification and In Vitro Fibrillization
FL a-syn (1–140), N-terminal or C-terminal-truncated a-syn (32–140, 58–140,
1–120), and 1–120 with a C-terminal Myc-tag (1–120-Myc) were expressed in
BL21 (DE3) RIL cells and purified as described (Giasson et al., 2001). Fibrilliza-
tion was conducted by diluting recombinant a-syn to 5 mg/ml in Dulbecco’s
PBS (Cellgro, Mediatech Inc; pH adjusted to 7.0) and incubating at 37C with
constant agitation at 1,000 rpm for 5–7 days. Successful fibrillization was
verified by sedimentation test and ThT-binding assay (see Extended Experi-
mental Procedures). Pffs were stored at room temperature to avoid freeze
and thaw.
Repetitive self-seeding was carried out by including 5% or 10% existing pffs
(0.25 or 0.5mg/ml in the final reaction) in a fibrillization reaction containing 95%
or 90% fresh monomers (4.75 or 4.5 mg/ml in the final reaction) for generating
the next passage of pffs, and the process was repeated until P10 (de novo pffs
considered as P1) (Figure 1B). For fibrillization directly seeded by strain A or
strain B pffs, 10% of existing pffs of either strain were added to a fibrillization
reaction containing 90% fresh monomers. All seeded fibrillization was per-
formed under the same conditions as de novo fibrillization. For each a-syn
construct, at least two independently prepared monomer batches were tested
for each fibrillization paradigm, and at least two series of self-seeded fibrilliza-
tion were set up for each monomer batch.
Biophysical Analyses of a-Syn pffs
1–120-Myc a-syn strain A and B pffs were sonicated and diluted to a final con-
centration of 5 mM in 10 mMNaH2PO4, 100 mM KF buffer (pH 7.3). CD spectra
were collected as described (Greenbaum et al., 2005). FL a-syn strain A and B
pffs were spun at 100,000 3 g for 15 min and resuspended in D2O. This pro-
cess was repeated two additional times, and then each sample was sonicated
50 times. FTIR spectra were collected as described earlier (Huang et al., 2002).
See Extended Experimental Procedures for details.
PK Digestion of a-Syn pffs
Ten micrograms of pffs were mixed with 1 to 2.5 mg/ml of PK in Dulbecco’s
PBS to a final volume of 20 ml and incubated at 37C for 30 min. Digestion
was stopped with 1 mM PMSF. Reaction samples were boiled with SDS-
sample buffer for 5 min and resolved on NuPAGE Novex 12% Bis-Tris gels
(Invitrogen). To identify the N-terminal sequences of PK-resistant fragments,
samples were transferred from 12% Bis-Tris gel to a sequencing-grade
PVDF membrane, and individual bands were submitted to the Keck Bio-
technology Resource Laboratory (Yale University) for N-terminal sequencing
analysis. Epitope mapping of the PK digestion products was performed by
immunoblotting samples that were transferred onto nitrocellulose membranes
with epitope-specific antibodies to a-syn (Table S1).
Primary Neuron Cultures and Fibril Transduction
Primary neuron cultures were prepared from embryonic day (E) 15–E17
embryos of non-Tg CD1mice (Charles River), a-syn knockout mice (Abeliovich
et al., 2000), and homo/het crosses of PS19 mice (Yoshiyama et al., 2007). All
procedures were performed according to the NIH Guide for the Care and Use
of Experimental Animals and were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee (IACUC). Dissociated hippocam-
pal neurons were plated onto poly-D-lysine-coated coverslips or dishes. Pff
transduction was performed at 6 days or 7 days in vitro, whereby a-syn pffsdopting strain A and B conformation.
fs in non-Tg neurons.
ially seeded by strain A pffs.
1–120 pffs that were seeded by strain B pffs.
ndent preparations of pffs tested: n = 5 for 10% seed control, n = 4 for FL, n = 5
ean ± SEM. **p < 0.005; ***p < 0.0005; ****p < 0.0001).
ults shown as scatterplot with mean ± SEM, ****p < 0.0001).
mm. See also Figure S4 and Table S3.
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Case No. Primary
Diagnosis
Secondary
Diagnosis
Sex Age at
death
PMI (h) Cingulate
LB score
Cingulate
NFT score
1 PDD - Male 59 10 3+ 0
2 PDD - Male 70 12.5 3+ 0
3 PDD AD Male 72 9 3+ 2+
4 PDD AD Male 74 12 3+ 3+
5 PDD AD Male 72 19 3+ 1+
A
B C D
   1     2    3     4    5
Undigested, syn211 Undigested, 17025 Digested, syn211
   1     2    3     4    5    1     2    3     4    5
Figure 7. Conformational Variations of
Pathological a-Syn in Synucleinopathy
Brains
(A) Demographics of PDD cases used for patho-
logical a-syn extraction from the cingulate gyrus.
Primary and secondary diagnoses are based on
neuropathological examination of postmortem
brains. PMI: postmortem interval. Pathological
scores of LBs and NFTs in the contralateral
cingulate gyrus are shown, with ‘‘3+’’ being the
highest score.
(B) Sarkosyl-insoluble fraction immunoblotted with
mAb Syn211 showed abundant a-syn for all five
cases.
(C) Sarkosyl-insoluble fraction from these five
cases showed varying extents of tau accumulation
revealed by pAb 17025.
(D) PK-digested sarkosyl-insoluble fraction
showed different banding patterns of PK-resistant
a-syn for PDD cases with or without abundant
coexisting AD pathologies.were diluted to 0.1 mg/ml in PBS and sonicated with 60 pulses before being
added to neuron medium. For each 13 mm coverslip, 2 mg of pffs were added,
and 8 mg of pffs were added per well for 6-well plates. Transduced neurons
were harvested for immunocytochemistry or sequential extraction at time
points indicated in the text (see Extended Experimental Procedures).
Cell-Survival Assays
LDH release assay and alamar blue assay were performed with CytoTox 96
Non-Radioactive Cytotoxicity Assay kit (Promega) and alamarBlue Cell
Viability Assay kit (Invitrogen), respectively, according to the manufacturers’
protocols (see Extended Experimental Procedures).
TEM and Immuno-EM
Negative-staining TEM of a-syn pffs and immuno-EM of transduced primary
neurons were performed as previously described (Guo and Lee, 2011; Volpi-
celli-Daley et al., 2011). For double-labeling immuno-EM, goat anti-mouse
IgG coupled to 10 nm colloidal gold and goat anti-rabbit IgG coupled to
6 nm colloidal gold (Electron Microscopy Sciences, Hatfield, PA, USA) were
used to visualize primary antibodies against a-syn and tau, respectively. See
Extended Experimental Procedures for details.
Antibody Generation and Application in Direct ELISA
HuA1 is an affinity-purified rabbit pAb raised against recombinant human
a-syn. 9029-03 is a mouse mAb raised against strain B FL a-syn fibrils, and
its conformational specificity was tested by direct ELISA, whereby 0.05–2 mg
of sonicated a-syn fibrils of strain A or B were loaded into each well. For direct
ELISA of different passages of a-syn fibrils, 0.5 mg of sonicated fibrils were
loaded per well. For quantification, absorbance of wells incubated with
9029-03 was normalized to absorbance of corresponding wells incubated
with HuA1. See Extended Experimental Procedures for details.
Stereotaxic Surgery and Immunohistochemistry
Unilateral inoculation of a-syn pffs into the hippocampus of 2- to 3-month-old
PS19 mice or C57BL6/C3H F1 mice (Charles River) was performed usingFigure 6. Strain-Specific Cross-Seeding of Tau Pathology In Vivo
(A) AT8-positive tau aggregates detected in different parts of ipsilateral hippocam
strain A or B 1–120-Myc pffs into the hippocampus of PS19 mice.
(B) Quantification of AT8-positive neurons in different parts of ipsilateral hippoca
post-injection of strain A, n = 3 for 6 months post-injection of strain B; results sh
(C) MC1 immunoreactivity in different parts of ipsilateral hippocampus at 3 mont
(D) tau inclusions cross-seeded by strain B pffs were recognized by TG3 and Ac
Scale bar: 100 mm. See also Figure S5.stereotaxic surgery as described (Iba et al., 2013) in accordancewith protocols
approved by the IACUC of the University of Pennsylvania. Immunohistochem-
ical analysis of injected mice was conducted at 3, 6, and 9 months post-
injection. See Extended Experimental Procedures for details.
PK Digestion of Sarkosyl-Insoluble Fraction from PDD Brains
Sarkosyl-insoluble fractions from the cingulate gyrus of PDD brains were
prepared as described in the Extended Experimental Procedures, and the
protein concentration was determined by bicinchoninic acid assay, so that
equal amounts of total proteins were used for PK digestion across different
samples, and PK concentration used was at a ratio of 33 103 to total protein
concentration. Human brain extracts were incubated with PK at 37C for
30 min, and reaction was stopped with 1 mM PMSF. Digested brain extracts
were resolved on NuPAGE Novex 12% Bis-Tris gels (Invitrogen), whereas un-
digested samples were resolved on 4%–12% Bis-Tris gels.
Statistical Analysis
Two-tailed unpaired Student’s t test was used for all the comparisons in the
study, and differences with p values less than 0.05 were considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.05.057.
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